Spots Global Cancer Trial Database for recurrent head and neck squamous cell carcinoma

Every month we try and update this database with for recurrent head and neck squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC	NCT02544880	Head and Neck S... Head and Neck C...	Tadalafil Anti-MUC1 Vacci... Anti-Influenza ... Tadalafil Place... Anti-MUC1 Vacci... Standard of Car... Anti-Influenza ...	18 Years -	University of Miami
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma	NCT03422536	Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an...	Cetuximab Ficlatuzumab	18 Years -	University of Arizona
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	NCT04643379	Recurrent Head ... Metastatic Head...	Olaparib Pembrolizumab Carboplatin Peripheral bloo...	18 Years -	Washington University School of Medicine
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC	NCT05726370	Head and Neck S... Head and Neck C... Resectable Head... Recurrent Head ...	Pembrolizumab CISPLATIN Carboplatin Docetaxel	18 Years -	Dana-Farber Cancer Institute
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	NCT04643379	Recurrent Head ... Metastatic Head...	Olaparib Pembrolizumab Carboplatin Peripheral bloo...	18 Years -	Washington University School of Medicine
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer	NCT04220775	Recurrent Head ... Second Primary ...	Bintrafusp Alfa Quality-of-Life... Questionnaire A... Stereotactic Bo...	18 Years -	M.D. Anderson Cancer Center
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer	NCT03521570	Recurrent Head ...	IMRT Nivolumab	18 Years -	Emory University
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC	NCT03813836	Metastatic Head... Recurrent Head ...	Pembrolizumab	18 Years -	University College, London
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma	NCT05980000	Recurrent Head ... Recurrent Head ... Recurrent Head ... Metastatic Head... Metastatic Head... HNSCC	Ramucirumab Pembrolizumab	18 Years -	Washington University School of Medicine
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer	NCT04834349	Recurrent Head ... Unresectable He...	Hafnium Oxide-c... Intensity-Modul... Intensity-Modul... Pembrolizumab Quality-of-Life... Questionnaire A... Stereotactic Bo...	18 Years -	M.D. Anderson Cancer Center
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)	NCT04282109	Recurrent Head ... Head and Neck C...	Nivolumab + Pac... Cetuximab + Pac...	18 Years -	Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
CIML NK Cell in Head & Neck Cancer	NCT04290546	Squamous Cell C... Recurrent Head ...	Interleukin-15 ... CIML NK cell In... Ipilimumab Cetuximab	18 Years -	Dana-Farber Cancer Institute
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer	NCT03521570	Recurrent Head ...	IMRT Nivolumab	18 Years -	Emory University
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	NCT01468896	Metastatic Head... Recurrent Head ... Unresectable He...	Cetuximab Edodekin alfa Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT03498378	Head and Neck S...	Avelumab Palbociclib Cetuximab	18 Years -	University of California, San Diego
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer	NCT05901545	Head and Neck S... Recurrent Head ...	Panitumumab Indium In 111 P... Single Photon E... Computed Tomogr... Surgical Proced... Imaging agent Intraoperative ... Near Infrared I... Electrocardiogr... Biospecimen Col...	19 Years -	Vanderbilt-Ingram Cancer Center
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT00494182	Metastatic Head... Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Paclitaxel Sorafenib	18 Years -	M.D. Anderson Cancer Center
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition	NCT04454489	Advanced Head a... Recurrent Head ... Metastatic Head... Stage III Cutan... Locally Advance... Stage IV Cutane...	Pembrolizumab (... Quad-shot palli...	18 Years -	Wake Forest University Health Sciences
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT05359692	Metastatic Head... Advanced Malign... Recurrent Head ...	INCAGN01876 retifanlimab	18 Years - 99 Years	Incyte Corporation
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat	NCT03823131	Metastatic Head... Recurrent Head ... Unresectable He...	ImmunoPulse Epacadostat Pembrolizumab CORVax Tavokinogene te...	18 Years -	University of California, San Francisco
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer	NCT04834349	Recurrent Head ... Unresectable He...	Hafnium Oxide-c... Intensity-Modul... Intensity-Modul... Pembrolizumab Quality-of-Life... Questionnaire A... Stereotactic Bo...	18 Years -	M.D. Anderson Cancer Center
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT03522584	Metastatic Head... Recurrent Head ...	Durvalumab Laboratory Biom... Stereotactic Bo... Tremelimumab Hypofractionate...	18 Years -	University of Washington
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC	NCT03813836	Metastatic Head... Recurrent Head ...	Pembrolizumab	18 Years -	University College, London
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	NCT01468896	Metastatic Head... Recurrent Head ... Unresectable He...	Cetuximab Edodekin alfa Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	NCT04671667	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Cisplatin Computed Tomogr... Intensity-Modul... Magnetic Resona... Pembrolizumab Proton Beam Rad...	18 Years - 79 Years	National Cancer Institute (NCI)
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer	NCT04576091	Clinical Stage ... Clinical Stage ... Recurrent Cutan... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Recurrent Paran... Recurrent Saliv... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Major... Stage III Oroph... Stage III Sinon... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Major ... Stage IV Oropha... Stage IV Sinona... Unresectable Cu... Unresectable He... Unresectable Hy... Unresectable La... Unresectable Or... Unresectable Or... Unresectable Pa... Unresectable Sa...	Biospecimen Col... Computed Tomogr... Elimusertib Pembrolizumab Positron Emissi... Quality-of-Life... Stereotactic Bo...	18 Years -	National Cancer Institute (NCI)
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	NCT05063552	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Lip ... Metastatic Nasa... Metastatic Naso... Metastatic Phar... Metastatic Sino... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Lip a... Recurrent Nasop... Recurrent Phary... Recurrent Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Nasoph... Stage IV Oropha... Stage IV Sinona...	Atezolizumab Bevacizumab Biospecimen Col... Carboplatin Cetuximab Cisplatin Computed Tomogr... Docetaxel Echocardiograph... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	NCT04588038	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Resectable Orop...	Efineptakin alf...	18 Years -	University of California, San Francisco
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT05359692	Metastatic Head... Advanced Malign... Recurrent Head ...	INCAGN01876 retifanlimab	18 Years - 99 Years	Incyte Corporation
PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC	NCT06239220	Head and Neck C... Head and Neck S... Metastatic Head... Recurrent Head ... Metastatic Head... Recurrent Head ...	PD-L1 t-haNK Cetuximab N-803	18 Years -	Dana-Farber Cancer Institute
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	NCT05743270	Squamous Cell C... Locally Advance... Recurrent Head ...	RP3 CCRT(concurrent... carboplatin and... nivolumab	18 Years -	Replimune Inc.
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC	NCT02544880	Head and Neck S... Head and Neck C...	Tadalafil Anti-MUC1 Vacci... Anti-Influenza ... Tadalafil Place... Anti-MUC1 Vacci... Standard of Car... Anti-Influenza ...	18 Years -	University of Miami
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC	NCT05156970	Recurrent Head ... Metastatic Head...	Camrelizumab Cisplatin Docetaxel Apatinib Mesyla... Carboplatin	18 Years - 75 Years	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	NCT04588038	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Resectable Orop...	Efineptakin alf...	18 Years -	University of California, San Francisco
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	NCT04671667	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Cisplatin Computed Tomogr... Intensity-Modul... Magnetic Resona... Pembrolizumab Proton Beam Rad...	18 Years - 79 Years	National Cancer Institute (NCI)
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer	NCT03521570	Recurrent Head ...	IMRT Nivolumab	18 Years -	Emory University
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer	NCT04375384	Head and Neck S... Recurrent Head ... Metastatic Head...	Cetuximab Questionnaire a... Quality of life...	18 Years -	Wake Forest University Health Sciences
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma	NCT06064877	Metastatic Head... Recurrent Head ...	Ficlatuzumab Cetuximab Placebo	18 Years -	AVEO Pharmaceuticals, Inc.
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	NCT04588038	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Resectable Orop...	Efineptakin alf...	18 Years -	University of California, San Francisco
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition	NCT04454489	Advanced Head a... Recurrent Head ... Metastatic Head... Stage III Cutan... Locally Advance... Stage IV Cutane...	Pembrolizumab (... Quad-shot palli...	18 Years -	Wake Forest University Health Sciences
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma	NCT03422536	Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an...	Cetuximab Ficlatuzumab	18 Years -	University of Arizona
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC	NCT05156970	Recurrent Head ... Metastatic Head...	Camrelizumab Cisplatin Docetaxel Apatinib Mesyla... Carboplatin	18 Years - 75 Years	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	NCT04671667	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Cisplatin Computed Tomogr... Intensity-Modul... Magnetic Resona... Pembrolizumab Proton Beam Rad...	18 Years - 79 Years	National Cancer Institute (NCI)
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer	NCT05945875	Head and Neck S... Recurrent Head ...	Panitumumab-IRD... Indium In 111 P... Single Photon E... Computed Tomogr... Resection Fluorescence Im...	19 Years -	Vanderbilt-Ingram Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: